Raymond James Financial Services Advisors Inc. increased its holdings in shares of GlaxoSmithKline PLC (NYSE:GSK) by 5.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 214,964 shares of the pharmaceutical company’s stock after acquiring an additional 11,978 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in GlaxoSmithKline PLC were worth $9,269,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Bingham Osborn & Scarborough LLC acquired a new position in GlaxoSmithKline PLC during the second quarter worth $311,000. 10 15 Associates Inc. grew its holdings in GlaxoSmithKline PLC by 6.4% during the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after acquiring an additional 14,247 shares during the period. Lincluden Management Ltd. grew its holdings in GlaxoSmithKline PLC by 1.7% during the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after acquiring an additional 1,990 shares during the period. Anchor Capital Advisors LLC grew its holdings in GlaxoSmithKline PLC by 9.6% during the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after acquiring an additional 53,894 shares during the period. Finally, Freestone Capital Holdings LLC grew its holdings in GlaxoSmithKline PLC by 11.9% during the second quarter. Freestone Capital Holdings LLC now owns 94,008 shares of the pharmaceutical company’s stock worth $4,054,000 after acquiring an additional 10,017 shares during the period. 9.28% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/10/11/glaxosmithkline-plc-gsk-position-lifted-by-raymond-james-financial-services-advisors-inc.html.
GlaxoSmithKline PLC (NYSE GSK) traded down 0.32% during mid-day trading on Wednesday, reaching $40.65. The company’s stock had a trading volume of 1,573,964 shares. The firm has a 50 day moving average price of $40.19 and a 200-day moving average price of $41.60. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.53. The company has a market capitalization of $99.97 billion, a PE ratio of 39.39 and a beta of 1.03.
GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a $0.491 dividend. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.82%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is presently 197.00%.
A number of research analysts recently weighed in on the company. Citigroup Inc. lowered GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Wednesday, July 5th. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, September 14th. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Finally, Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. GlaxoSmithKline PLC has a consensus rating of “Hold” and a consensus price target of $44.67.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
What are top analysts saying about GlaxoSmithKline PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline PLC and related companies.